The mechanism underlying the therapeutic effects of Deep Brain Stimulation (DBS) surgery needs investigation. The methods presented in this manuscript describe an experimental approach to examine the cellular events triggered by DBS by analyzing the gene expression profile of candidate genes that can facilitate neurogenesis post DBS surgery.
Deep brain stimulation (DBS) surgery, targeting various regions of the brain such as the basal ganglia, thalamus, and subthalamic regions, is an effective treatment for several movement disorders that have failed to respond to medication. Recent progress in the field of DBS surgery has begun to extend the application of this surgical technique to other conditions as diverse as morbid obesity, depression and obsessive compulsive disorder. Despite these expanding indications, little is known about the underlying physiological mechanisms that facilitate the beneficial effects of DBS surgery. One approach to this question is to perform gene expression analysis in neurons that receive the electrical stimulation. Previous studies have shown that neurogenesis in the rat dentate gyrus is elicited in DBS targeting of the anterior nucleus of the thalamus1. DBS surgery targeting the ATN is used widely for treatment refractory epilepsy. It is thus of much interest for us to explore the transcriptional changes induced by electrically stimulating the ATN. In this manuscript, we describe our methodologies for stereotactically-guided DBS surgery targeting the ATN in adult male Wistar rats. We also discuss the subsequent steps for tissue dissection, RNA isolation, cDNA preparation and quantitative RT-PCR for measuring gene expression changes. This method could be applied and modified for stimulating the basal ganglia and other regions of the brain commonly clinically targeted. The gene expression study described here assumes a candidate target gene approach for discovering molecular players that could be directing the mechanism for DBS.
The history behind the development of Deep Brain Stimulation as a neurosurgical technique dates back to the 1870s when the possibility of electrically stimulating the brain circuitry was explored2. The use of chronic high-frequency stimulation as treatment for neuronal disorders started in the 1960s3. Later in the 1990s with the advent of chronic implantation DBS electrodes4-6, the number of neuronal disorders that were treated by DBS continued to increase. Deep Brain Stimulation was first used in the United States as a treatment for essential tremor6. Today the surgery is used widely to treat neuronal disorders that are currently untreatable by pharmacological intervention. DBS is currently used to treat movement disorders of Parkinson’s disease and dystonia7-9. Alzheimer’s type dementia, Huntington’s disease, epilepsy, pain and neuropsychiatric diseases such depression, OCD, Tourette’s syndrome and addiction are some of the conditions amenable to treatment by DBS10-12. While DBS surgery is FDA approved for treating Parkinson’s disease, dystonia and essential tremor, the use of DBS for treating other conditions mentioned above are in various stages of lab and clinical studies offering much promise to patients13,14.
Clinically, DBS surgery is performed in two stages. The first stage involves surgically positioning the DBS electrodes at the targeted anatomical location using a combination of radiological positioning, CT, MRI as well as microelectrode readings for enhanced precision. The second stage involves implanting a pulse generator in the patient’s upper chest and installing extension leads from the scalp to the pulse generator. Based on the neurological condition, several programming schemes for the pulse generator have been standardized and will be used to deliver the desired voltage. The final voltage is reached in a stepwise fashion so as to receive the best clinical response with minimal voltage15. However, in our studies, unlike the chronic DBS implants used clinically, for the sake of simplicity, we have resorted to studying a one-time high frequency stimulation (for 1 hr) in our animal models.
Part of our group’s research focuses on investigating the use of DBS surgery for treatment-refractory epilepsy. Stereotactic surgical approaches using high frequency stimulation has been explored by many others as an effective option to treat medically-refractory epilepsy which constitutes about 30% of all incidences of epilepsy10,16,17. Cerebellar stimulation targeting the cortical surface as well as the deep cerebellar nuclei have been used in the past as targets to treat epilepsy10,18,19. In addition, hippocampus stimulation has also been tried but with mixed results20,21. Some of the other investigated DBS targets for epilepsy include the cerebral cortex, thalamus, subthalamic nucleus and vagus nerve8. However, following results from several studies in the past few years, the anterior thalamic nucleus (ATN) has emerged as the most common DBS target for epilepsy treatment10,22. Based on knowledge about neuroanatomical circuitry and findings from animal models, several studies have focused on the therapeutic effect of deep brain stimulation of the ATN in treating epilepsy 23-26. The ATN is part of the limbic circuit and is located in the region of the brain that affects seizure frequency. Studies by Hamani et al., have tested the efficacy of ATN-DBS in a pilocarpine induced epilepsy model and found that bilateral ATN stimulation prolonged latencies for pilocarpine-induced seizures and status epilepticus24. Furthermore, high frequency stimulation of the ATN was found to reduce seizure frequency in a pentylenetetrazol (PTZ) model of epilepsy25,27-29. Lee et al., have reported a mean reduction in seizure frequency by about 75% upon chronic deep brain stimulation of the ATN in treating refractory partial epilepsy30.
A recent clinical study on treatment-refractory epilepsy has shown promising results after DBS surgery targeting the anterior thalamic nucleus (ATN)22. A multicenter randomized clinical trial with 110 patients undergoing bilateral DBS of the ATN for treatment refractory epilepsy (SANTE trial) indicated a drop in seizure frequency by approximately 40%31. The results from this study also hinted on a delayed optimal anti-epileptic effect observed at 2-3 months post surgery. Further studies by Toda et al., corroborated with these findings where they demonstrated neurogenesis happening at a later time post DBS (days 3-5) in animal models1. In addition, Encinas et al., have reported hippocampal neurogenesis in the adult mouse dentate gyrus after high frequency stimulation of the ATN32. Previous studies33-35 have reported declining hippocampal neurogenesis in certain epileptic cases such as chronic temporal lobe epilepsy and an association with learning deficits, memory impairment and spontaneous recurrent motor seizures. Furthermore, there was a reduction in neural stem cell progenitor factors such as FGF2 and IGF-1 in the chronically epileptic hippocampus in animal models 33. Considering this, interventional strategies such as DBS that show an augmentation of neurogenesis in the dentate gyrus are exciting avenues for research. These findings have encouraged us to explore further deeply into the mechanism underlying neurogenesis post-DBS treatment for epilepsy. We have targeted the ATN both unilaterally (data not reported) as well as bilaterally (in representative results) and seen elevated neurotrophin (BDNF) expression in the rat dentate gyrus. Our current hypothesis is that BDNF expression initiates a gene expression cascade that culminates in neurogenesis that translates to the anti-epileptic effect of DBS surgery. In this paper, we present our methods for DBS surgery targeting the ATN in rats followed by gene expression analysis as an attractive approach to study the mechanism underlying the benefits of DBS.
NOTE: Ethics Statement: All procedures discussed in this manuscript are in accordance with the NIH guidelines for Animal Research (Guide for the Care and Use of Laboratory Animals) and are approved by the Harvard Medical School IACUC Committee.
1. Pre-surgical Preparation
2. DBS Surgery
3. Hippocampus Isolation
NOTE: Perform all the subsequent steps in this section on ice.
4. RNA Extraction and Quantitative PCR
5. Removing DNA from the RNA Preparation
6. Making cDNA from RNA
7. Quantitative PCR
Figures 1A and 1B show the relative expression of BDNF and GABRD relative to the control gene β-actin. BDNF, a neurotrophin is often associated with neuroprotective effects in many neuronal diseases38-41. It is therefore interesting to analyze the expression profile of BDNF in response to stimulation of the ATN which yields therapeutic benefits to epileptic patients. In Figure 1A which shows the gene expression profile of BDNF across the indicated time-points post DBS stimulation, BDNF up-regulation is observed immediately (0 hr) after DBS surgery along with the peak expression (3 fold greater than unstimulated) at 3 hr post stimulation. This observation suggests that enhanced BDNF expression and the resulting neuroprotection could contribute to the therapeutic benefit of DBS. Another gene GABRD (Figure 1B) was also investigated using the qPCR method. GABRD is a GABA receptor which is one of the potential targets for designing anti-epilepsy drugs42. The expression profile of GABRD also shows enhanced expression in the stimulated animals compared to the unstimulated control animals at 3 hr post DBS. Considering that GABA agonists are used as effective seizure suppressors, it is interesting to observe enhanced GABRD expression post DBS, implicating a possible role for GABA in the anti-epileptic effect of DBS.
The RT-PCR protocol described here yields reproducible and quantitative results that reveal gene expression patterns and the relative fold differences compared to the control animals. The data analysis is performed in the following manner: The qPCR output gives the threshold Ct value for the test gene for each sample analyzed. Ct values are also obtained for the control gene β-actin and 18S rRNA (input control). The ΔΔCt method will then be used to calculate the gene expression profile using these Ct values37. For example, to calculate the gene expression changes for BDNF, for a given sample, the difference between the Ct value for BDNF and 18S rRNA is calculated and is the first ΔCt. For the same sample, the difference between the Ct value for β-actin and 18S rRNA is calculated to give the second ΔCt. The difference between the two ΔCt values is calculated to give ΔΔCt. This ΔΔCt value is used to calculate 2^ (-ΔΔCt) which gives the relative template abundance for BDNF compared to β-actin. By plotting this value across the different time-points alongside the unstimulated control, the gene expression changes induced by DBS across time-points can be visualized. The above described method could be used effectively to investigate changes in expression for other genes which are potential candidates that are responsive to DBS stimulation and to investigate some of the downstream effects of modulating the expression of these genes.
Figure 1: (A) Time course analysis of BDNF expression in response to high frequency stimulation of the ATN. Tissue harvesting, RNA extraction, cDNA preparation and q-PCR were performed as explained in the protocol. Relative changes in gene expression are calculated after normalizing for input (by amplifying 18S rRNA) as well as a control gene (β-actin). Ct values obtained from the real-time PCR were used to calculate expression levels by the ΔΔ Ct method 37. The time-points analyzed are 0, 3, 6 and 12 hr post DBS stimulation. Note: The timepoints selected here are with respect to a particular study and is subject to change according to the hypothesis and experimental plan. (B) Time course analysis of GABA A receptor delta subunit (GABRD) levels in response to DBS at 130 Hz targeting the ATN. Methods and calculations were done as similar to the BDNF data.
Figure 2: DBS electrodes and stimulator set up.
PCR Cycles | |||
Stage 1: | Initial Denaturation | 95 °C | 15 min |
Stage 2: | Denaturation | 95 °C | 15 sec |
Annealing | 60 °C | 30 sec | |
Extension | 72 °C | 30 sec | |
40 cycles of Step 2 | |||
Note: The annealing temperature varies according to the | |||
primer melting temperature. Primers are typically designed | |||
to have an optimal annealing temperature of 60 °C |
Table 1: PCR Parameters.
Following the landmark work by Benabid et al. in using deep brain stimulation to treat Parkinson’s disease and essential tremor, the DBS surgical technique has been investigated with much interest over the past decade to treat many neurological disorders6,10,43. DBS studies targeting various neuro-anatomical regions of the brain circuitry are currently performed by many groups to address major neuronal diseases and are in various stages of clinical trials. Stimulation of the subthalamic nucleus (STN) or the internal segment of the globus pallidus (GPi) is FDA approved and used in treating movement disorders in Parkinson’s disease10. The SANTE clinical trial has shown promising trends for epileptic patients receiving high frequency stimulation of the anterior thalamic nucleus31. Results from a phase I clinical trial of bilateral forniceal stimulation have shown a delay in the rate of cognitive decline and a reversal of the glucose hypometabolic uptake seen in Alzheimer’s disease as well as activation of the memory circuitry8,44. Furthermore, in recent years neurosurgeons have conducted DBS trials for treating neuropsychiatric disorders such as OCD (Obsessive Compulsive Disorder), treatment-resistant depression, Tourette syndrome and addiction10,45-55.
In addition to the clinical trials, over the past few years, animal surgery has offered us great opportunities to study the physiological changes induced by the surgical technique in a live animal, in a manner unparalleled by any in vitro technique. In this manuscript, we have discussed the methods involved in performing deep brain stimulation surgery in rodents. Stereotactic surgery in rodents as described here could also be used for potential DBS target searches and to test out the efficacy of the surgery using disease model animals. One of the challenges for the experimenter here is to be able to target the correct anatomical locus in a reproducible manner. There is especially a need for a skilled technician for the surgery because checking for correct targeting is possible only after the stimulation is done and the animal euthanized. Also occasionally, one might accidentally injure a key blood vessel which could lead to significant blood loss and sometimes even death of the animal. In addition, the need to dissect out the hippocampus for further biochemical analysis limits the possibility of immunohistological verification for proper electrode targeting in the same animal which requires an intact brain specimen for tissue sectioning. Proper electrode targeting could possibly be checked on a different animal stimulated in an identical manner. However, this does not provide evidence for proper targeting in the test animal and is a limitation of this approach. Recent publications have tried to circumvent this problem by conducting DBS surgery with simultaneous fMRI56. One possible improvement of the technique described here could be a study on the effects of chronic stimulation via an implanted stimulator in the animal. However, we have limited our analysis for a single dose (1 hr) of high-frequency stimulation as the first step to understanding the changes induced by DBS at a cellular level.
Considering the use of DBS surgery for a variety of neuronal disorders, it is essential that we know the mechanism underlying the beneficial effects of DBS. This information is critical for developing future improvements in the surgery and also to explore the utility of DBS as a treatment for other conditions which haven’t been investigated by experts in DBS. In addition, modifications to the surgical technique can be implemented to avoid certain deleterious side-effects of the procedure and to effectively deal with recurrence of the disease condition.
An in-depth mechanistic analysis of DBS is possible by examining the gene expression changes induced by DBS. Either a candidate gene approach based on existing knowledge about neuronal pathways that respond to depolarizing stimuli such as high frequency stimulation, or a global transcriptome analysis can give important insights into the molecular events triggered by DBS. The gene expression analysis techniques (candidate gene approach as well as high-throughput method) are powerful tools that are key to exploring the molecular mechanisms and cellular changes associated with DBS surgery. Recent developments in this area have made it possible for us to get a wealth of information about several aspects of cellular physiology in a very short time, which was not possible a few years ago. With the advent of high throughput sequencing technology such as ChIPseq, it is possible to characterize the genome-wide location of important transcription factors which respond to DBS57,58. Recent discoveries linking non-coding RNA such as microRNA with neurodegenerative diseases, enable us to analyze possible changes in miRNA levels in neurons post-DBS using miRNA sequencing technology59,60. Possible changes in epigenetic signatures such DNA methylation and histone modifications in response to DBS could also be explored. However, despite the advantages, it is important to acknowledge some of the limitations of these techniques as well as potential problems that might arise during analyses. An important concern with gene expression analyses has been reproducibility and technical errors. It is important that the experimenter takes note of this and plans on having adequate number of repetitions to ensure reliability. A common problem with some of the high throughput screening studies has been the difficulty in interpretation of the tremendous amount of data that is generated. Sometimes it becomes important to determine whether the gene expression changes observed are due to the direct effect of the experimental treatment or is a downstream effect. This usually requires additional studies that are designed to address this issue.
In addition to the genomic studies, an extensive immunohistochemical analysis of the spatio-temporal localization of the key players that respond to DBS and a quantitation of the changes in their levels in various regions of the brain will be a great asset to future developments of the DBS surgical procedure. The cumulative findings from the gene expression analyses as well as the immunohistochemical studies can reveal novel interactions between key factors as well as key molecular events that regulate cellular processes such as neurogenesis or neurodegeneration. Identification of such critical molecular markers may also enable future drug discoveries. Such findings could shed light on the general functioning of the brain circuitry, which is valuable information from the perspective of scientists working to understand many neuronal diseases. Directing our future efforts on integrating latest technological advances made in the clinic as well as the laboratory is likely to offer us substantial advantages in our fight against disease.
The authors have nothing to disclose.
We are grateful for the support of the NREF foundation.
Deep Brain Stimulation Surgery | |||
Reagent/Equipment | Vendor Name | Catalog No. | Comments |
Stereotactic frame | Kopf Instruments | Model 900 | |
Drill | Dremmel | 7700, 7.2 V | |
Scalpel | BD | 372610 | |
Ketamine | Patterson Veterinary | 07-803-6637 | Schedule III Controlled Substance, procurement, use and storage according to institutional rules |
Xylazine | Patterson Veterinary | 07-808-1947 | |
Buprenorphine | Patterson Veterinary | 07-850-2280 | Schedule III Controlled Substance, procurement, use and storage according to institutional rules |
Surgical staples | ConMed Corporation | 8035 | |
Sutures (3-0) | Harvard Apparatus | 72-3333 | |
Syringe (1 ml, 29 1/2 G) | BD | 329464 | Sterile, use for Anesthesia administration intraperitoneally |
Syringe (3 ml, 25 G) | BD | 309570 | Sterile, use for Analgesia administration subcutaneously |
Needles | BD | 305761 | Sterile, use for clearing broken bone pieces from the burr holes |
Ethanol | Fisher Scientific | S25309B | Use for general sterilization |
Eye Lubricant | Fisher Scientific | 19-898-350 | |
Stimulator | Medtronic | Model 3628 | |
DBS electrodes | Rhodes Medical Instruments, CA | SNEX100x-100mm | Electrodes are platinum, concentric and bipolar |
Betadine (Povidone-Iodine) | PDI | S23125 | Single use swabsticks, use for sterilizing the scalp before making incision |
Brain Dissection and Hippocampal tissue isolation | |||
Reagent/Equipment | Vendor Name | Catalog No. | Comments |
Acrylic Rodent Brain Matrix | Electron Microscopy Sciences | 175-300 | www.emsdiasum.com |
Razor Blade | V W R | 55411-050 | |
Guillotine Scissors | Clauss | 18039 | For decapitation, make sure these scissors are maintained in clean and working condition |
Scissors | Codman Classic | 34-4098 | Use for removing the brain from the skull |
Forceps | Electron Microscopy Sciences | 72957-06 | Use for removing the brain from the skull and for handling during dissection |
Phosphate Buffered Saline | Boston Bioproducts | BM-220 | |
RNA Extraction and cDNA Preparation | |||
Reagent/Equipment | Vendor Name | Catalog No. | Comments |
Tri Reagent | Sigma | T9424 | Always use in a fume hood and wear protective goggles while handling; avoid contact with skin |
Syringe (3 ml, 25 G) | BD | 309570 | Use for tissue homogenization |
Chloroform | Fisher Scientific | BP1145-1 | Always use in a fume hood and wear protective goggles while handling; avoid contact with skin |
Isopropanol | Fisher Scientific | A416-1 | |
Glycogen | Thermo Scientific | R0561 | |
Dnase I Kit | Ambion | AM1906 | |
Superscript First Strand Synthesis Kit | Invitrogen | 11904-018 | |
Tabletop Microcentrifuge | Eppendorf | 5415D | |
Quantitative PCR | |||
Reagent/Equipment | Vendor Name | Catalog No. | Comments |
SYBR Green PCR Kit | Qiagen | 204143 | |
Custom Oligos | Invitrogen | 10668051 | |
PCR Plates (96 wells) | Denville Scientific | C18080-10 | |
Optical Adhesive Sheets | Thermo Scientific | AB1170 | |
Nuclease free Water | Thermo Scientific | SH30538-02 | |
Real Time PCR Machine | Applied Biosystems | 7500 |